Medical Science
FDA Approves Lipfendra, the First Daily Oral PCSK9 Cholesterol Drug
The U.S. Food and Drug Administration has approved Lipfendra, also known by its generic name enlicitide, as the first oral medication to block PCSK9—a biological target previously addressed only through injectable cholesterol-lowering treatments. The once-daily tablet is approved alongside diet and exercise to reduce low-density